136 related articles for article (PubMed ID: 23701359)
21. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose.
Christoph P; Schuller C; Studer H; Irion O; De Tejada BM; Surbek D
J Perinat Med; 2012 May; 40(5):469-74. PubMed ID: 22945271
[TBL] [Abstract][Full Text] [Related]
22. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
23. Nanoparticle-assisted laser desorption/ionization using sinapic acid-modified iron oxide nanoparticles for mass spectrometry analysis.
Komori H; Hashizaki R; Osaka I; Hibi T; Katano H; Taira S
Analyst; 2015 Dec; 140(24):8134-7. PubMed ID: 26535417
[TBL] [Abstract][Full Text] [Related]
24. Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design.
Szczech LA; Bregman DB; Harrington RA; Morris D; Butcher A; Koch TA; Goodnough LT; Wolf M; Onken JE
Nephrol Dial Transplant; 2010 Jul; 25(7):2368-75. PubMed ID: 20466657
[TBL] [Abstract][Full Text] [Related]
25. Parenteral iron sucrose in iron deficiency anaemia of paediatric chronic kidney disease.
Moorani KN; Asim S
J Ayub Med Coll Abbottabad; 2011; 23(3):47-50. PubMed ID: 23272434
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial.
Goldstein SL; Morris D; Warady BA
Am J Kidney Dis; 2013 Apr; 61(4):588-97. PubMed ID: 23245582
[TBL] [Abstract][Full Text] [Related]
27. Characterization of reaction intermediate aggregates in aniline oxidative polymerization at low proton concentration.
Ding Z; Sanchez T; Labouriau A; Iyer S; Larson T; Currier R; Zhao Y; Yang D
J Phys Chem B; 2010 Aug; 114(32):10337-46. PubMed ID: 20701368
[TBL] [Abstract][Full Text] [Related]
28. Determination of iron sucrose (Venofer) or iron dextran (DexFerrum) removal by hemodialysis: an in-vitro study.
Manley HJ; Grabe DW
BMC Nephrol; 2004 Jan; 5():1. PubMed ID: 14718064
[TBL] [Abstract][Full Text] [Related]
29. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial.
Singh H; Reed J; Noble S; Cangiano JL; Van Wyck DB;
Clin J Am Soc Nephrol; 2006 May; 1(3):475-82. PubMed ID: 17699248
[TBL] [Abstract][Full Text] [Related]
30. Evolution of iv iron compounds over the last century.
Macdougall IC
J Ren Care; 2009 Dec; 35 Suppl 2():8-13. PubMed ID: 19891680
[TBL] [Abstract][Full Text] [Related]
31. Analysis of total and transferrin-bound iron in human serum for pharmacokinetic studies of iron-sucrose formulations.
Goggin MM; Gozum SD; Burrows DM; Nguyen A; Corcoran HF; Dotzauer H; Tann CM; Lundberg RA; Janis GC
Bioanalysis; 2011 Aug; 3(16):1837-46. PubMed ID: 21877893
[TBL] [Abstract][Full Text] [Related]
32. Optimized steric stabilization of aqueous ferrofluids and magnetic nanoparticles.
Jain N; Wang Y; Jones SK; Hawkett BS; Warr GG
Langmuir; 2010 Mar; 26(6):4465-72. PubMed ID: 19950943
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of high-dose intravenous iron carboxymaltose vs. iron sucrose for treatment of postpartum anemia.
Pfenniger A; Schuller C; Christoph P; Surbek D
J Perinat Med; 2012 Apr; 40(4):397-402. PubMed ID: 22752771
[TBL] [Abstract][Full Text] [Related]
34. Iron (III) isomaltoside 1000.
Mace TA; Syed A; Bhandari S
Expert Rev Hematol; 2013 Jun; 6(3):239-46. PubMed ID: 23782077
[TBL] [Abstract][Full Text] [Related]
35. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose.
Neiser S; Rentsch D; Dippon U; Kappler A; Weidler PG; Göttlicher J; Steininger R; Wilhelm M; Braitsch M; Funk F; Philipp E; Burckhardt S
Biometals; 2015 Aug; 28(4):615-35. PubMed ID: 25801756
[TBL] [Abstract][Full Text] [Related]
36. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
Schröder O; Mickisch O; Seidler U; de Weerth A; Dignass AU; Herfarth H; Reinshagen M; Schreiber S; Junge U; Schrott M; Stein J
Am J Gastroenterol; 2005 Nov; 100(11):2503-9. PubMed ID: 16279906
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial.
Charytan C; Levin N; Al-Saloum M; Hafeez T; Gagnon S; Van Wyck DB
Am J Kidney Dis; 2001 Feb; 37(2):300-7. PubMed ID: 11157370
[TBL] [Abstract][Full Text] [Related]
38. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
[TBL] [Abstract][Full Text] [Related]
39. Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: a randomized trial.
Froessler B; Cocchiaro C; Saadat-Gilani K; Hodyl N; Dekker G
J Matern Fetal Neonatal Med; 2013 May; 26(7):654-9. PubMed ID: 23130909
[TBL] [Abstract][Full Text] [Related]
40. Inulin-iron complexes: a potential treatment of iron deficiency anaemia.
Pitarresi G; Tripodo G; Cavallaro G; Palumbo FS; Giammona G
Eur J Pharm Biopharm; 2008 Feb; 68(2):267-76. PubMed ID: 17574404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
